Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Ewa Wasik-Szczepanek, Ozren Jaksic, Mihnea Zdrenghea, Uri Greenbaum, Inga Mandac, Martin Simkovic, Marta Morawska, Ohad Benjamini, Martin Spacek, Anatoly Nemets, Osnat Bairey, Livio Trentin, Rosa Ruchlemer, Luca Laurenti, Oana Stanca CiocanMichael Doubek, Lev Shvidel, Nagib Dali, Fátima Mirás, Anne De Meûter, Maria Dimou, Francesca R. Mauro, Marta Coscia, Horia Bumbea, Róbert Szász, Tamar Tadmor, Odit Gutwein, Massimo Gentile, Lydia Scarfò, Alessandra Tedeschi, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet, Sarit Assouline, Maria Papaioannou, Andrei Braester, Luciano Levato, Michael Gregor, Gian M. Rigolin, Javier Loscertales, Angeles Medina Perez, Marten R. Nijziel, Viola M. Popov, Rosa Collado, Irma Slavutsky, Gilad Itchaki, Shimrit Ringelstein, Neta Goldschmidt, Chava Perry, Shai Levi, Aaron Polliack, Paolo Ghia

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group'. Together they form a unique fingerprint.

Medicine & Life Sciences